Elpis has closed a funding round backed by top life sciences investors. The funds will be used to grow the company’s catalogue of human cell type products and expand its service offerings. This marks our first step towards more complex products, including human organ-on-chip models, and cell-based therapies.
Jonathan Milner PhD, co-founder and Deputy Chairman of Abcam said: “I’m thrilled to be backing Mark Kotter and his team at Elpis BioMed. Elpis’ approach to making human cells is truly disruptive – it reduces manufacturing time and at the same time increases purity by an order of magnitude. But what is most important: it allows for unprecedented levels of consistency and minimal batch-to-batch variability.”
Read the full press release here.